HSBC Holdings’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.36M Sell
148,182
-352,814
-70% -$20.6M ﹤0.01% 982
2025
Q4
$29.8M Buy
500,996
+220,995
+79% +$12M 0.02% 631
2025
Q3
$15.1M Sell
280,001
-93,116
-25% -$5.33M 0.01% 796
2025
Q2
$20.5M Buy
373,117
+47,083
+14% +$2.77M 0.01% 702
2025
Q1
$23M Buy
326,034
+130,504
+67% +$8.78M 0.01% 671
2024
Q4
$12.8M Sell
195,530
-4,865
-2% -$326K 0.01% 854
2024
Q3
$14.1M Buy
200,395
+110,600
+123% +$9.25M 0.01% 826
2024
Q2
$7.41M Sell
89,795
-142,903
-61% -$11.9M ﹤0.01% 943
2024
Q1
$20.3M Sell
232,698
-196,359
-46% -$17.6M 0.01% 695
2023
Q4
$41.3M Sell
429,057
-178,041
-29% -$15.8M 0.04% 467
2023
Q3
$53.9M Buy
607,098
+434,199
+251% +$38.6M 0.06% 345
2023
Q2
$15M Sell
172,899
-18,888
-10% -$1.78M 0.02% 700
2023
Q1
$18.7M Sell
191,787
-104,788
-35% -$10.9M 0.02% 634
2022
Q4
$30.4M Buy
296,575
+195,495
+193% +$18.4M 0.03% 505
2022
Q3
$8.62M Buy
101,080
+44,955
+80% +$4M 0.01% 946
2022
Q2
$4.68M Sell
56,125
-28,150
-33% -$2.24M 0.01% 1224
2022
Q1
$6.53M Buy
84,275
+34,713
+70% +$2.9M 0.01% 1081
2021
Q4
$4.41M Sell
49,562
-35,335
-42% -$2.92M ﹤0.01% 1320
2021
Q3
$6.56M Buy
84,897
+31,007
+58% +$2.45M 0.01% 1044
2021
Q2
$4.49M Buy
53,890
+11,160
+26% +$885K ﹤0.01% 1143
2021
Q1
$3.23M Sell
42,730
-5,478
-11% -$447K ﹤0.01% 1156
2020
Q4
$4.2M Sell
48,208
-21,535
-31% -$1.71M 0.01% 1090
2020
Q3
$5.33M Buy
69,743
+27,931
+67% +$2.83M 0.01% 927
2020
Q2
$5.16M Sell
41,812
-11,739
-22% -$1.17M 0.01% 850
2020
Q1
$4.49M Buy
53,551
+20,266
+61% +$1.75M 0.01% 886
2019
Q4
$2.82M Sell
33,285
-8,285
-20% -$626K ﹤0.01% 1365
2019
Q3
$2.8M Buy
41,570
+15,493
+59% +$1.19M 0.01% 1446
2019
Q2
$2.23M Sell
26,077
-11,107
-30% -$950K ﹤0.01% 1480
2019
Q1
$3.3M Sell
37,184
-238,585
-87% -$22.1M 0.01% 1283
2018
Q4
$23.5M Buy
275,769
+55,006
+25% +$5.23M 0.04% 433
2018
Q3
$21.4M Buy
220,763
+199,861
+956% +$19.9M 0.03% 524
2018
Q2
$1.97M Sell
20,902
-16,890
-45% -$1.48M ﹤0.01% 1510
2018
Q1
$3.06M Sell
37,792
-1,450
-4% -$124K ﹤0.01% 1285
2017
Q4
$3.5M Buy
39,242
+13,724
+54% +$1.19M 0.01% 951
2017
Q3
$2.37M Sell
25,518
-720
-3% -$63.6K ﹤0.01% 1260
2017
Q2
$2.38M Buy
26,238
+8,184
+45% +$745K ﹤0.01% 1221
2017
Q1
$1.59M Sell
18,054
-18,635
-51% -$1.66M ﹤0.01% 1283
2016
Q4
$3.04M Sell
36,689
-6,903
-16% -$594K 0.01% 1104
2016
Q3
$4.03M Sell
43,592
-4,858
-10% -$457K 0.01% 970
2016
Q2
$3.77M Sell
48,450
-32,585
-40% -$2.77M 0.01% 1005
2016
Q1
$6.68M Sell
81,035
-125
-0.2% -$10.2K 0.02% 786
2015
Q4
$8.5M Sell
81,160
-19,406
-19% -$2.03M 0.02% 747
2015
Q3
$10.6M Sell
100,566
-3,741
-4% -$500K 0.03% 581
2015
Q2
$14.2M Buy
104,307
+42,580
+69% +$5.28M 0.03% 528
2015
Q1
$7.69M Buy
61,727
+10,967
+22% +$1.16M 0.01% 765
2014
Q4
$4.59M Buy
50,760
+14,280
+39% +$1.19M 0.01% 923
2014
Q3
$2.63M Sell
36,480
-296,822
-89% -$19.5M 0.01% 1078
2014
Q2
$20.7M Buy
333,302
+98,803
+42% +$5.97M 0.04% 404
2014
Q1
$16M Buy
234,499
+218,010
+1,322% +$16.1M 0.04% 429
2013
Q4
$1.16M Buy
16,489
+6,098
+59% +$414K ﹤0.01% 1232
2013
Q3
$750K Buy
10,391
+8,438
+432% +$561K ﹤0.01% 1294
2013
Q2
$109K Buy
+1,953
New +$122K ﹤0.01% 1492

Other funds holding BMRN

HSBC Holdings's BMRN Position: Q1 2026 in Review

HSBC Holdings reduced its BioMarin Pharmaceuticals (BMRN) stake by 70% in Q1 2026, selling an estimated $20.6M and leaving 148,182 shares worth $8.36M. The position accounts for ﹤0.01% of the portfolio, ranked #982.

HSBC Holdings first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $53.9M in Q3 2023. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • HSBC Holdings held 148,182 shares of BioMarin Pharmaceuticals worth $8.36M as of Q1 2026.
  • HSBC Holdings sold 352,814 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $20.6M.
  • BioMarin Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #982 holding.
  • HSBC Holdings first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • HSBC Holdings's BioMarin Pharmaceuticals position peaked at $53.9M in Q3 2023.
  • 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.